Capricor Therapeutics Inc (NASDAQ: CAPR) on Tuesday, plunged -6.46% from the previous trading day, before settling in for the closing price of $15.95. Within the past 52 weeks, CAPR’s price has moved between $3.52 and $23.40.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 434.62% annually for the last half of the decade. The company achieved an average annual earnings per share of -43.37%. With a float of $39.97 million, this company’s outstanding shares have now reached $40.33 million.
In an organization with 102 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 95.71%, operating margin of -154.68%, and the pretax margin is -146.86%.
Capricor Therapeutics Inc (CAPR) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Capricor Therapeutics Inc is 12.10%, while institutional ownership is 39.05%. The most recent insider transaction that took place on Sep 20 ’24, was worth 14,999,998. In this transaction 10% Owner of this company bought 2,798,507 shares at a rate of $5.36, taking the stock ownership to the 7,090,351 shares.
Capricor Therapeutics Inc (CAPR) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.35 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -43.37% per share during the next fiscal year.
Capricor Therapeutics Inc (NASDAQ: CAPR) Trading Performance Indicators
Capricor Therapeutics Inc (CAPR) is currently performing well based on its current performance indicators. A quick ratio of 4.19 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 29.20.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.06, a number that is poised to hit -0.17 in the next quarter and is forecasted to reach -0.98 in one year’s time.
Technical Analysis of Capricor Therapeutics Inc (CAPR)
Let’s dig in a bit further. During the last 5-days, its volume was 1.35 million. That was better than the volume of 0.88 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 78.16%. Additionally, its Average True Range was 1.04.
During the past 100 days, Capricor Therapeutics Inc’s (CAPR) raw stochastic average was set at 46.92%, which indicates a significant decrease from 52.68% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 68.97% in the past 14 days, which was lower than the 138.62% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.19, while its 200-day Moving Average is $10.53. However, in the short run, Capricor Therapeutics Inc’s stock first resistance to watch stands at $16.00. Second resistance stands at $17.07. The third major resistance level sits at $17.68. If the price goes on to break the first support level at $14.31, it is likely to go to the next support level at $13.70. The third support level lies at $12.63 if the price breaches the second support level.
Capricor Therapeutics Inc (NASDAQ: CAPR) Key Stats
Market capitalization of the company is 678.41 million based on 45,470K outstanding shares. Right now, sales total 25,180 K and income totals -22,290 K. The company made 2,260 K in profit during its latest quarter, and -12,560 K in sales during its previous quarter.
